Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort-Reference-Cited by-同舟云学术

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Published:2010-01 Issue:9712 Volume:375 Page:377-384
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gianni Luca,Eiermann Wolfgang,Semiglazov Vladimir,Manikhas Alexey,Lluch Ana,Tjulandin Sergey,Zambetti Milvia,Vazquez Federico,Byakhow Mikhail,Lichinitser Mikhail,Climent Miguel Angel,Ciruelos Eva,Ojeda Belén,Mansutti Mauro,Bozhok Alla,Baronio Roberta,Feyereislova Andrea,Barton Claire,Valagussa Pinuccia,Baselga Jose

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute;Hance;J Natl Cancer Inst,2005

2. Breast carcinoma survival in Europe and the United States;Sant;Cancer,2004

3. Locally advanced and inflammatory breast cancer;Chia;J Clin Oncol,2008

4. Addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate and fluorouracil, as adjuvant or primary systemic therapy: results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO);Gianni;J Clin Oncol,2009

5. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry;Zell;Breast Cancer Res,2009

Cited by 1037 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosomes-based immunotherapy for cancer: Effective components in the naïve and engineered forms;International Immunopharmacology;2024-09

2. Cross-validated risk scores adaptive enrichment (CADEN) design;Contemporary Clinical Trials;2024-09

3. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

4. In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab;International Journal of Molecular Sciences;2024-08-27

5. Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study;Frontiers in Oncology;2024-08-21